Wedge Capital Management L L P NC Trims Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Wedge Capital Management L L P NC decreased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 45.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 32,216 shares of the specialty pharmaceutical company's stock after selling 26,466 shares during the quarter. Wedge Capital Management L L P NC owned 0.15% of ANI Pharmaceuticals worth $1,781,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Assenagon Asset Management S.A. increased its position in ANI Pharmaceuticals by 67.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 311,617 shares of the specialty pharmaceutical company's stock valued at $17,226,000 after acquiring an additional 125,438 shares during the period. JPMorgan Chase & Co. increased its holdings in ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock valued at $33,101,000 after purchasing an additional 340,854 shares during the period. Principal Financial Group Inc. increased its holdings in ANI Pharmaceuticals by 6.9% in the third quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company's stock valued at $5,367,000 after purchasing an additional 5,829 shares during the period. Franklin Resources Inc. raised its position in ANI Pharmaceuticals by 6.1% during the 3rd quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company's stock worth $705,000 after purchasing an additional 691 shares during the last quarter. Finally, Hohimer Wealth Management LLC acquired a new position in ANI Pharmaceuticals during the 3rd quarter worth about $264,000. Institutional investors own 76.05% of the company's stock.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the transaction, the chief financial officer now owns 154,468 shares in the company, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the business's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the sale, the senior vice president now directly owns 49,059 shares of the company's stock, valued at approximately $2,943,540. This trade represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,381 shares of company stock worth $2,441,556 over the last 90 days. Corporate insiders own 12.70% of the company's stock.

Wall Street Analysts Forecast Growth

ANIP has been the topic of a number of analyst reports. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price objective on the stock. Truist Financial increased their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a report on Tuesday, October 22nd. HC Wainwright reissued a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Piper Sandler started coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an "overweight" rating and a $68.00 price target on the stock. Finally, Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, ANI Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $77.71.

ANI Pharmaceuticals Stock Performance

ANIP traded down $0.02 during trading on Tuesday, hitting $58.44. 79,826 shares of the company traded hands, compared to its average volume of 207,403. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $70.81. The stock's fifty day moving average is $56.30 and its 200 day moving average is $58.78. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a market cap of $1.23 billion, a P/E ratio of -106.26 and a beta of 0.73.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating analysts' consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. ANI Pharmaceuticals's revenue was up 12.5% compared to the same quarter last year. During the same period last year, the business earned $1.05 earnings per share. As a group, equities analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.